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KEY MESSAGE
The most frequently reported complication after an HSG with oil-based contrast is intravasation, occurring 
in 2.7% of HSG procedures. In total only four cases with serious consequences of oil embolisms in subfertile 
women were published. Therefore, safety concerns should not be the reason to deny the use of oil-based 
contrast for tubal testing in women with unexplained subfertility.
ABSTRACT
Recent meta-analyses have shown that a hysterosalpingography (HSG) with oil-based contrast increases pregnancy 
rates in subfertile women. However, the frequency of complications during or after an HSG with oil-based contrast in 
subfertile women and/or their offspring is still unclear. This systematic review and meta-analysis, without restrictions 
on language, publication date or study design, was performed to fill this knowledge gap. The results show that 
the most frequently reported complication was intravasation of contrast, which occurred in 2.7% with the use of 
oil-based contrast (31 cohort studies and randomized controlled trials [RCT], 95% CI 1.7–3.8, absolute event rate 
664/19,339), compared with 2.0% with the use of water-based contrast (8 cohort studies and RCT, 95% CI 1.2–3.0, 
absolute event rate 18/1006). In the cohort studies and RCT there were 18 women with an oil embolism (18/19,339 
HSG), all without serious lasting consequences. Four cases with serious consequences of an oil embolism were 
described (retinal oil embolism [n = 1] and cerebral complaints [n = 3]); these reports did not describe the use 
of adequate fluoroscopy guidance during HSG. In conclusion, the most frequently reported complication after an 
HSG with oil-based contrast is intravasation occurring in 2.7%. In total four cases with serious consequences of oil 
embolisms in subfertile women were published.
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INTRODUCTION
H ysterosalpingography (HSG) to assess tubal patency is an essential part of the work-up for subfertile couples 
(National Institute for Health and 
Care Excellence, 2017). The first HSG 
was performed in 1910 by Rindfleisch 
(Rindfleisch, 1910). From 1914 iodized 
oils were used as an alternative to the 
water-based contrasts, which were 
irritative to the peritoneum (Cary, 1914; 
Nielsen, 1946; Soules and Spadoni, 1982). 
Different iodized oils were introduced, 
such as Lipiodol®, Iodochlorol, Ethiodol, 
Jodipin, Jodumbrin and Lipiodol® 
Ultra Fluid. The oil-based contrasts 
available today are Lipiodol® Ultra 
Fluid (Guerbet, Villepinte, France) and 
Ethiodized Poppyseed Oil (Heng Rui 
Pharmaceuticals, Jiangsu, China), the 
latter being currently only available in 
Asia.
Lipiodol was developed in 1901 as a 
solution containing iodine, and was 
used for a wide range of indications, 
including the reduction of struma 
and infection prevention. After the 
discovery of its radiological qualities, it 
was used for visualization of the uterine 
cavity and Fallopian tubes, but also in 
myelography, bronchography and later in 
lymphography. In 1960 a transesterified 
version of Lipiodol was developed, 
Lipiodol Ultra Fluid, which had a lower 
viscosity (Bonnemain and Guerbet, 1995; 
Simescu et al., 2002).
For nearly seven decades, the 
therapeutic effect of oil-based contrast 
during HSG in the fertility work-up 
has been debated. Recently two meta-
analyses have shown a favourable 
effect of oil-based contrast on fertility 
outcomes, with an OR of 1.47 (95% CI 
1.12–1.93) for ongoing pregnancy and 2.18 
(95% CI 1.30–3.65) for live birth when 
comparing HSG with oil-based contrast 
to water-based contrast (Fang et al., 
2018; Wang et al., 2019). This generated 
a worldwide renewed interest in the 
use of oil-based contrast for fertility 
enhancement. However, some clinicians 
are still hesitant about its use because of 
complications that have been reported in 
the past.
In 1929 the first report of intravasation 
of oil-based contrast during HSG was 
published (Pujol y Brull et al., 1929). 
Intravasation is the inflow of contrast 
in the venous or lymphatic system, 
and is visualized by radiography, ideally 
with the use of fluoroscopy screening. 
Even though water-based contrast can 
also intravasate, only oil-based contrast 
is known to enter the circulation as 
droplets because of its hydrophobic 
qualities. These oil droplets can reach 
organs such as the lungs or brain as oil 
emboli and cause inflammation and/or 
occlusion of the vasculature (Uzun et al., 
2004). After this first case, more reports 
of intravasation followed, but most 
patients had only minor symptoms and 
recovered after observation. Intravasation 
was therefore regarded as innocuous 
(Soules and Spadoni, 1982). Currently, 
intravasation with the use of oil-based 
contrast is estimated to occur in around 
5% of the HSG in the Netherlands (Roest 
et al., 2020).
In spite of this, a recent case report 
describes a patient falling into a 
comatose state as a result of an oil 
embolus after HSG (Uzun et al., 
2004). Although this might be a rare 
complication, it does emphasize the 
importance of safety and knowledge of 
the complication rates after HSG with 
the use of oil-based contrast.
As previously mentioned, Lipiodol 
contains iodine, and the iodine 
concentration in Lipiodol is higher than 
in water-based contrast (480 mg iodine/
ml in Lipiodol versus 240–300 mg 
iodine/ml in water-based contrast). 
Iodine exposure can cause a transient 
decrease in the synthesis of thyroid 
hormone (Wolff and Chaikoff, 1948). 
Subclinical hypothyroidism is associated 
with pregnancy complications (van den 
Boogaard et al., 2011). Furthermore, the 
HSG procedure has a risk of infection.
The systematic reviews and meta-
analyses to date have primarily focused 
on fertility outcomes and have excluded 
case reports. This systematic review and 
meta-analysis included all study types, 
to provide an overview of the frequency 
and clinical consequences of all possible 
complications during or after HSG with 
the use of oil-based contrast in subfertile 
women.
MATERIALS AND METHODS
The protocol of this review was 
prospectively registered on PROSPERO 
(https://www.crd.york.ac.uk/prospero/, 
registration ID: CRD42018102382, 
registration date: 24 July 2018). The 
methodology used was as described 
in the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis 
(PRISMA) statement (Moher et al., 2009).
Information sources and search 
strategies
Electronic databases including 
MEDLINE, EMBASE and the Cochrane 
Central Register of Controlled Trials 
(CENTRAL) were searched up to June 
2020. Textbooks as well as reference 
lists of identified publications were also 
manually screened. The key search 
items included ‘hysterosalpingography’, 
‘oil contrast’, ‘ethiodized oil’, ‘ethiodol’, 
‘lipiodol’, ‘adverse effect’, ‘side effect’, 
‘complication’, ‘thyroid’, ‘intravasation’, 
‘embolization’, ‘granuloma’, ‘anaphylaxis’, 
‘pelvic inflammatory disease’, and 
‘adnexitis’ (Supplementary Tables 1–3).
Eligibility criteria
All types of studies were included: 
randomized controlled trials (RCT), 
prospective and retrospective cohort 
studies, case series and case reports that 
report complications occurring during 
or after HSG with the use of oil-based 
contrast, with or without comparison to 
water-based contrast, in women trying to 
conceive or their offspring. No limitations 
on language or publication period were 
applied. Colleagues who were fluent 
in the foreign languages assisted in 
translating.
Outcomes
The outcomes included adverse events 
of HSG with the use of oil-based 
contrast (versus water-based contrast) 
in subfertile women and their offspring, 
such as: intravasation of the contrast 
medium, embolization of the contrast 
medium, pelvic inflammatory disease, 
lipogranuloma formation, retention 
of contrast, maternal or fetal thyroid 
dysfunction, and anaphylactic reactions. 
The clinical consequences included 
additional treatments, hospital stay, 
morbidity and mortality.
Study selection, data collection and 
quality assessment
Study eligibility was evaluated by two 
reviewers (IR and KR) independently; 
disagreements between the two 
reviewers were solved by consensus or 
by consultation with another reviewer 
(CK) when necessary. A predesigned 
form was used to extract the data and 
assess the quality of the included studies. 
 RBMO  VOLUME 42  ISSUE 6  2021 1121
The following information was collected: 
name of the first author, publication 
year, study design, study population, 
participants’ characteristics, types of 
contrast, details of interventions and 
co-interventions, sample sizes and 
outcomes. Full-text articles of English 
cohort and randomized studies were 
screened by a second reviewer (KR).
Risk of bias was assessed for all studies, 
excluding the case reports/series, in 
accordance with the quality assessment 
checklist for prevalence studies (Hoy 
et al., 2012) (Supplementary Table 4). 
This checklist contains nine questions, 
each scored with 0 or 1 points. A total of 
0–3 points is classified as an overall low 
risk of study bias, 4–6 points as moderate 
risk and 7–9 points as high risk. The risk 
of bias was assessed by two reviewers 
independently for the English studies.
Statistical analysis
The prevalence of complications 
occurring with the use of oil-based 
contrast was calculated, and where 
possible comparisons were made 
to the use of water-based contrast. 
Meta-analyses were performed 
using Review Manager Version 5.3. 
Statistical heterogeneity was estimated 
by performing a chi-squared test 
and calculating I2. Pooled weighted 
prevalences and the 95% CI were 
calculated using the MetaXL tool (Version 
5.3, 2016; EpiGear International Pty 
Ltd, Queensland, Australia). A non-
pre-specified sensitivity analysis was 
performed, selecting the cohorts and 
RCT to calculate the prevalence of 
complications. Case reports and case 
series were included to report all (and 
rare) complications.
RESULTS
Characteristics of included studies
The search identified 492 records. A 
total of 8 RCT, 41 cohort studies (4 
prospective cohorts, 24 retrospective 
cohorts, 13 cohort studies which were 
not further specified) and 59 case 
reports/case series were included 
within the review. In these studies, a 
total of 23,536 HSG procedures were 
performed with the use of oil-based 
contrast (23,298 HSG in cohort studies/
RCT). Sixteen of the included studies 
reported on HSG with water-based 
contrast as well, with a total of 1,975 HSG 
with water-based contrast (1,973 HSG in 
cohort studies/RCT) (for flow chart see 
Supplementary Figure 1). The included 
studies were published between 1928 
and 2020 (see Supplementary Table 5 
for the characteristics of the included 
studies) (Alper et al., 1986; Aznar et al., 
1969; Bang, 1950; Barqawi et al., 2007; 
Bateman et al., 1980; Bergin, 1951; 
Bersi, 1977; Binder et al., 1976; Bohm 
and Seewald, 1972; Böttger and Fleck, 
1955; Brent et al., 2006; Brown et al., 
1949; Buytaert and Meulyzer, 1977; 
Charawanamuttu et al., 1973; Claus 
and Dochez, 1966; Coventry, 1934; Dan 
et al., 1990; Dreyer et al., 2017; Drukman 
and Rozin, 1951; Effkemann, 1935; Eisen 
and Goldstein, 1945; Elliott et al., 1965; 
Faris and McMurrey, 1947; Feiner, 1942; 
Flew, 1944; Fochem and Ulm, 1954; 
Frischkorn, 1958; Geary et al., 1969; 
Gotoh et al., 2010; Grant et al., 1957; 
Grosskinsky et al., 1994; Grossmann, 
1946; Gunsberger, 1958; Heinen and 
Schussler, 1966; Hemmeler, 1938; Hirst, 
1928; Hohlbein, 1965; Ishizuki et al., 
1992; Johnson et al., 2004; Kaneshige 
et al., 2015; Karshmer and Stein, 1951; 
Kika, 1954; Kilroe and Hellman, 1933; 
Kuzavova, 1964; La Sala et al., 1982; 
Lau, 1969; Levinson, 1963; Li et al., 2018; 
Lin and Tsou, 1935; Lindequist et al., 
1991, 1994; Liu et al., 2010; Ma et al., 
2016; Mackey et al., 1971; Madsen, 1942; 
Malter and Fox, 1972; Meaker, 1934; 
Mekaru et al., 2008; Miyazaki et al., 
2020; Morii et al., 2013; Netter and 
Weill-Fage, 1950; Nordio, 1938; Norris, 
1956; Novak, 1930; Nugent et al., 2002; 
Nunley et al., 1987; Omoto et al., 2013; 
Palmer, 1960; Pear and Boyden, 1967; 
Piatt, 1947; Porcher, 1935; Pujol y Brull 
et al., 1929; Rasmussen et al., 1987; Riche 
and Fayot, 1931; Ries, 1929; Robins and 
Shapira, 1951; Rubin, 1928; Rutherford, 
1948; Sappey et al., 1952; Sasaki et al., 
2017; Satoh et al., 2015; Schaffer, 1954; 
Schultze, 1932; Schutte et al., 2006; 
Schwabe et al., 1983; Shapiro et al., 1957; 
Slater et al., 1959; So et al., 2017; Solal, 
1932; Steiner et al., 2003; Stoll and Zeitz, 
1956; Takeyama et al., 2014; Tan et al., 
2019; Ueda et al., 2016; Uzun et al., 
2004; van Welie et al., 2020; Vara, 1950; 
Volk, 1936; Weise et al., 1973; Weitzner, 
1935; Werner, 1952; Williams, 1944; 
Witwer et al., 1930; Woltz et al., 1958; 
Wong et al., 1932; Yamazaki et al., 2019; 
Zachariae, 1955; Zacharin, 1933).
Quality of evidence of the studies
Of the 49 cohort studies and RCT, 
16 studies were classified as low risk, 
31 studies as moderate risk and two 
studies as high risk of study bias. In 18 
studies, there was no clear definition 
of the reported complications. Mainly, 
there was no predefined definition of 
intravasation or oil embolism. There is 
no reliable or valid classification method 
for intravasation, therefore 44 of the 48 
studies were classified as high risk of bias 
for the reliability and validity of the study 
instrument that measured the parameter 
of interest (see Supplementary Table 6 
for the classification of all studies).
Intravasation and oil embolisms
Eight studies (three RCT and five cohort 
studies) compared the frequency of 
intravasation between HSG with the use 
of oil-based and water-based contrast 
(FIGURE 1) (Alper et al., 1986; Barqawi 
et al., 2007; Frischkorn, 1958; Lindequist 
et al., 1991, 1994; Liu et al., 2010; Tan 
et al., 2019; Zachariae, 1955). Rates of 
intravasation were 2.8% (38/1353) after 
HSG with oil-based contrast and 1.8% 
(18/1006) after HSG with water-based 
contrast (OR 5.05; 95% CI 2.27–11.22; 
P < 0.0001) based on the RCT and 1.23 
(95% CI 0.50–3.07; P = 0.65) based 
on the cohort studies), showing that 
intravasation occurs more frequently with 
the use of oil-based contrast.
Twenty-three additional cohort 
studies reported on the prevalence of 
intravasation with the use of oil-based 
contrast alone. The overall pooled 
weighted frequency of intravasation in 
the 31 RCT and cohort studies with 
the use of oil-based contrast was 2.7% 
(95% CI 1.7–3.8, absolute event rate 
664/19,339), compared with 2.0% (95% 
CI 1.2–3.0, absolute event rate 18/1,006) 
in the eight studies with the use of water-
based contrast. When including only 
studies published from 2000 onwards, 
the pooled frequency of intravasation 
with the use of oil-based contrast was 
2.8% (95% CI 1.2–5.1, absolute event rate 
12/471), compared with 1.8% (95% CI 
0.0–5.9, absolute event rate 8/403) with 
the use of water-based contrast.
In the whole group of HSGs with the 
use of oil-based contrast performed in 
RCT and cohort studies, there were 18 
women with oil embolisms (18/19,339, 
0.1% of HSG; 18/664, 2.7% of cases 
with intravasation). In six of these cases 
pulmonary embolisms were described, 
while the other 12 cases only described 
the contrast moving rapidly out of the 
pelvis. The latter were all asymptomatic 
and serious lasting consequences were 
not reported (see FIGURE 2).
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FIGURE 2 Intravasation and oil embolisms in HSG with oil-based contrast for subfertility in 
cohort studies and RCT. HSG = hysterosalpingography; RCT = randomized controlled trial.
FIGURE 1 Prevalence of intravasation of oil-based contrast versus water-based contrast in HSG for subfertility. Forest plot of meta-analysis 
reporting on intravasation with the use of oil-based contrast compared with water-based contrast. (A) RCT. (B) Cohort studies. OR and 95% CI. 
OR < 1 favour oil-based contrast (fewer adverse events); OR > 1 favour water-based contrast (fewer adverse events). The risk of bias of individual 
studies is represented by coloured dots: green (low risk of bias) and yellow (moderate risk of bias). HSG = hysterosalpingography; OSCM = oil-
based contrast media; RCT = randomized controlled trial; WSCM = water-based contrast media.
Additionally, there were 197 cases of 
intravasation after an HSG with the use 
of oil-based contrast in the case reports/
series. In 22 of these women this led to 
the formation of an oil embolism (22/197, 
11.2%). Four of these women were 
asymptomatic, 18 were symptomatic. 
Symptoms included a transient cough 
and/or dyspnoea and neurological 
symptoms. Four cases were described of 
women with serious consequences of an 
oil embolism (TABLE 1) (Charawanamuttu 
et al., 1973; Dan et al., 1990; Flew, 1944; 
Uzun et al., 2004).
When including only the studies 
(including the case reports) that used 
fluoroscopy screening, there were 250 
women with intravasation after an HSG 
with the use of oil-based contrast. In 
this group there were 16 women with 
oil embolisms (16/250, 6.4%), of which 
two had symptoms of coughing and one 
temporary impaired vision as a result of 
a retinal oil embolism (3/16, 18.8%). The 
authors reported that the fluoroscopy 
images were of poor quality, and over 
20 ml of contrast was used during this 
last procedure (Charawanamuttu et al., 
1973).
When excluding the studies with known 
fluoroscopy guidance, there were 611 
women with intravasation after an HSG 
with the use of oil-based contrast. In 
this group there were 24 women with 
oil embolisms (24/611, 3.9%), of which 
19 (19/24, 79.2%) had, mostly transient, 
pulmonary symptoms. Of the 24 women 
with oil embolisms there were three 
women with serious lasting consequences 
of cerebral complaints after an oil 
embolism (TABLE 1) (Dan et al., 1990; Flew, 
1944; Uzun et al., 2004).
Infection
Two RCT and 18 cohort studies reported 
on the frequency of infection after HSG 
with the use of oil-based contrast. The 
overall pooled weighted frequency of 
infection was 0.90% (95% CI 0.47–1.50, 
70/11,287 women). Two RCT and two 
cohort studies compared HSG with the 
use of oil-based contrast to HSG using 
water-based contrast. The frequency of 
infection with the use of water-based 
contrast was 1.9% (95% CI 0.27–4.60, 
17/564 women). Including only the 
studies published in or after 1960, the 
overall pooled frequency of infection 
was 0.55% (95% CI 0.23–1.00) after 
HSG with the use of oil-based contrast 
and 0.35% (95% CI 0.00–7.30) with 
the use of water-based contrast. The 
use of antibiotic prophylaxis was not 
systematically reported.
Mortality
Five cases of mortality were reported 
after HSG with the use of oil-based 
contrast in subfertile women. Four of 
these cases were infection-related, 
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and they were published in the period 
between 1942 and 1950 (Bang, 1950; 
Feiner, 1942; Rutherford, 1948).
The fifth case described a woman that 
passed away minutes after a recurrent 
HSG with 9 ml of lipoiodine under light 
cyclopropane anaesthesia, possibly due 
to an allergic reaction to the oil-based 
contrast or the anaesthesia used (Faris 
and McMurrey, 1947).
Additionally, two cases were reported 
in 1928 and 1930 where tubal blockage 
was found on the HSG. These women 
underwent surgery 1 and 5 days later, 
and died shortly after, presumably from 
infectious complications of the surgery 
(Hirst, 1928; Novak, 1930).
Lipogranuloma and oil remnants
Eleven studies reported on 41 women 
with lipogranuloma formation after an 
HSG with the use of different types of 
oil-based contrast. These included three 
cohort studies, one case series and 
seven case reports. The contrasts used 
were: Lipiodol not further specified (33 
cases), oil-based/iodized contrast not 
further specified (five cases), Jodipin 
(two cases), Ethiodol (one case). In 
nine cases histology examination was 
mentioned, in 32 cases this was not 
mentioned.
Additionally, there were 85 reports of oil 
remnants after an HSG with the use of 
oil-based contrast. These were reported 
in nine studies; three cohort studies 
and six case reports. Forty-four cases 
were discovered within 2 weeks after the 
procedure, while 41 were discovered up 
to 27 years after the HSG procedure. 
Fifty-six cases were diagnosed after 
laparoscopy; 29 cases were diagnosed 
after radiology imaging. Histological 
examination was only reported in one 
case.
Thyroid dysfunction
TABLE 2 shows four cohort studies and 
four case reports/series on maternal 
TABLE 1 CHARACTERISTICS OF SERIOUS CONSEQUENCES OF OIL EMBOLISM AFTER HSG
Study Contrast Risk factors Organ system involved Consequences
Flew, 1944 Lipiodol (not specified) HSG on day 24 of menstrual cycle; 
use of fluoroscopy not reported
Pulmonary and cerebrum Hemiplegia, survived
Charawanamuttu 
et al., 1973
Lipiodol Ultra Fluid >20 ml of contrast, poor definition 
of fluoroscopy images
Pulmonary and retina 3 months of impaired vision
Dan et al., 1990 Lipiodol Ultra Fluid Use of fluoroscopy not reported Pulmonary, central nervous 
system
Comatose for 11 days, afterwards normal 
mental/motor function
Uzun et al., 2004 Lipiodol (not specified) Use of fluoroscopy not reported Pulmonary, central nervous 
system
Comatose for 10 days, afterwards mental/
motor function progressively improved
HSG = hysterosalpingography.
TABLE 2 MATERNAL THYROID FUNCTION AFTER HSG
Study design Procedure Thyroid function pre-HSG Outcome
Case reports
Li et al., 2018 China Oil-based contrast Unknown Fourteen women with increased urinary iodine content: 50% (7/14) 
(subclinical) hypothyroidism. All neonates tested negative during 
congenital thyroid screening.
Sasaki et al., 2017 Japan Oil-based contrast Unknown Case of hypothyroidism, no treatment. Fetal goitre.
Ma et al., 2016 China Oil-based contrast
100 ml
Euthyroid Hyperthyroidism, no treatment, resolved spontaneously after 1.5 
months.
Ishizuki et al., 1992 Japan Lipiodol Graves’ disease Thyroiditis, goitre, treated with steroids for 2 months.
Cohorts/RCT
So et al., 2017 Japan Lipiodol
Max 5 ml
Euthyroid Oil-based contrast: 22.6% subclinical hypothyroidism after 1–30 days, 
24.4% after 31–180 days.
Water-based contrast: 9.5% subclinical hypothyroidism after 1–30 






Euthyroid: 27% goitre palpable 0% hypothyroidism (0/22).
13.6% (3/22) transient subclinical hypothyroidism.





Euthyroid: 4/180 (2.2%) hypothyroidism, 28/180 (15.6%) subclinical 
hypothyroidism, 2/180 (1.1%) subclinical hyperthyroidism.
Subclinical hypothyroidism: 10/28 (35.7%) hypothyroidism, three 
required thyroid hormone replacement. 1/28 (3.6%) subclinical 
hyperthyroidism.
Subclinical hyperthyroidism: 4/12 (33.3%) normalization, 2/12 (16.7%) 
unchanged.
Slater et al., 1959 USA Lipiodol Clinically euthyroid Oil-based contrast: 80% depression of iodine uptake, increase in 
protein-bound iodine for 4 months.
Water-based contrast: no depression of iodine uptake. Increase in 
protein-bound iodine for 24–48 h.
HSG = hysterosalpingography.
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thyroid function after HSG with the use 
of oil-based contrast.
Three cases of fetal goitre following 
an HSG with oil-based contrast were 
reported. In two of the cases the HSG 
had been performed in the month of 
conception (10 ml of Lipiodol and an 
unknown volume of unspecified oil-
based contrast was used); in the third 
case three HSGs had been performed 
in the year before conception. In one 
case intra-amniotic levothyroxine was 
administered as treatment. After birth, 
hypothyroidism was diagnosed in one 
of the newborns, which resolved by day 
7. The other neonates were euthyroid. 
One of the mothers had hypothyroidism 
during pregnancy; two were euthyroid. 
In one of the mothers, oil remnants were 
present in the abdominal cavity on a 
post-partum X-ray (Omoto et al., 2013; 
Sasaki et al., 2017; Yamazaki et al., 2019).
One retrospective cohort study from 
Japan (Satoh et al., 2015) evaluated the 
neonatal thyroid function after HSG 
with the use of Lipiodol. Abnormal 
congenital thyroid screening was seen in 
2.4% (5/212); three cases of subclinical 
hypothyroidism and two cases of overt 
hypothyroidism. The median volume 
of contrast in the group with thyroid 
dysfunction was significantly higher than 
the group with normal thyroid function 
(20 ml [range 10–20 ml] versus 8 ml 
[range 3–25 ml], P = 0.033). However, 
the volume was only reported for three 
out of five neonates with abnormal 
thyroid function test results. Another 
retrospective cohort study investigated 
the thyroid function of 140 neonates 
born after a preconceptional HSG with 
oil-based contrast, Lipiodol Ultra Fluid 
(n = 76) or water-based contrast, Telebrix 
Hystero® (n = 64). None of the neonates 
tested positive during the congenital 
hypothyroidism screening. Furthermore, 
the volume of contrast used did not 
influence the thyroid function (median of 
9.0 ml of oil-based contrast) (van Welie 
et al., 2020).
Other complications
One case of a tubal rupture, without ill 
effects, was described. The diagnostic 
method was not reported (Witwer et al., 
1930). Additionally, one case report 
described abdominal pain, like Fitz-
Hugh–Curtis syndrome, possibly due to 
the chemical stimulation of the iodized 
oil (not further specified) used during an 
HSG (Morii et al., 2013).
HSG performed for non-subfertility 
indications
The primary intention of this study was to 
take into account HSGs performed for 
subfertility. However, in a non-systematic 
way, the study also identified one case 
of a massive oil embolism leading to 
death, published in 1931. A 60-year-old 
received an HSG with 8 ml Jodipin for 
postmenopausal blood loss which was 
suspected for malignancy. A massive oil 
embolism occurred in the cerebrum, 
pituitary gland, liver, spleen, kidney 
and heart, and the patient died within 
5 h after the procedure. The use of 
fluoroscopy screening was not reported. 
It is likely that no adequate fluoroscopy 
was performed at the time (Gajzago, 
1931).
Furthermore, a case report of a woman 
falling into a comatose state after an 
HSG was reported. This woman had had 
two unsuccessful curettage attempts for 
termination of pregnancy, after which 
she received an HSG with Lipiodol Ultra 
Fluid. The endometrium was injured 
after the several curettages, and so 
the contrast could flow directly into 
the bloodstream, leading to a massive 
intravasation with oil embolisms. After 
81 days she was discharged with slight 
mental deficit (Ogihara et al., 1991).
This study also identified case reports 
of pulmonary oil embolisms after 
HSG performed in patients with: 
tubal ligation (n = 2) (Roblee, 1945), 
suspected endometrium carcinoma 
(n = 1) (Breitländer and Hinrichs, 1941), 
abdominal pain (n = 1) (Ingersoll and 
Robbins, 1947), uterus myomatosus 
(n = 2) (Hodge and Price, 1969; Keller, 
1943) and missed abortion (n = 1) (Hinaut 
et al., 1966).
DISCUSSION
In this review of articles published 
from 1928 onwards, including a total of 
23,536 HSG with the use of oil-based 
contrast, the most frequently reported 
complication of HSG performed for 
subfertility was intravasation of contrast. 
This occurred in 2.7% of the HSG 
with the use of oil-based contrast (31 
studies, 95% CI 1.7–3.8), compared 
with 2.0% with the use of water-based 
contrast (8 studies, 95% CI 1.2–3.0) 
derived from cohort studies and RCT. 
Oil embolisms occurred in 0.1% of the 
HSG performed in cohort studies and 
RCT. In all studies, including the case 
reports, the percentage of symptomatic 
oil embolisms was strikingly lower in the 
group with fluoroscopy guidance during 
HSG compared with no fluoroscopy 
guidance (19% versus 79%). With the use 
of fluoroscopy guidance during HSG, no 
serious consequences of oil embolisms 
occurred.
The frequency of infection with the use 
of oil-based contrast was 0.90% (20 
studies, 95% CI 0.47–1.50), compared 
with 1.9% (four studies, 95% CI 
0.27–4.60) with the use of water-based 
contrast.
One case of non-infection-related 
mortality after an HSG, most likely due 
to an anaphylactic reaction, was reported 
in 1947.
There were 85 reports of oil remnants 
after an HSG. Half of the cases were 
diagnosed within 2 weeks of the 
procedure. Furthermore, there were 41 
reports of lipogranuloma formation.
Women with subclinical hypothyroidism 
seem more likely to develop 
hypothyroidism after an HSG with oil-
based contrast (35.7% versus 0–2.2% in 
euthyroid women), however this is based 
on only 28 and 202 women, respectively 
(Kaneshige et al., 2015; Mekaru et al., 
2008; So et al., 2017). Results on the 
effect on thyroid function of the offspring 
are contradictory; a Japanese study 
showed abnormal congenital thyroid 
screening in 2.4% whereas a Dutch study 
did not show any abnormalities (Satoh 
et al., 2015; van Welie et al., 2020).
This is the first systematic review on the 
safety of HSG with oil-based contrast 
that includes all study types. Another 
strength of this systematic review is that 
no restriction on language or publication 
date was applied.
However, the systematic review has 
limitations. First, the quality of the 
included studies was moderate to low. 
This is attributable to the design and 
the publication year of the included 
studies. In most of the studies the 
primary outcome was pregnancy-related. 
Complications were often reported as 
secondary outcomes.
Second, the development of fluoroscopy 
guidance during HSG has helped 
clinicians to diagnose intravasation 
and oil embolisms, leading to timely 
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termination of the HSG procedure. This 
development is suggested as the reason 
for the increase in reported cases of 
intravasation and oil embolisms, however 
as mentioned previously, the percentage 
of symptomatic oil embolisms has 
therefore drastically decreased.
Oil embolisms, also known as fat 
embolisms, have not only been reported 
in the gynaecological literature. Bone 
marrow fat embolisms occur in 11–19% of 
trauma or orthopaedic surgery patients 
(Mellor and Soni, 2001). Fat embolisms 
may cause a fat embolism syndrome, 
with clinical symptoms varying from right 
heart failure and cardiovascular collapse 
to hypoxemia, pyrexia, petechial rash 
and neurological symptoms (Mellor and 
Soni, 2001). When reaching the lungs, 
the fatty substance mixes with the locally 
secreted lipase. Free fatty acids are 
released, causing inflammation to the 
pulmonary microvasculature and leading 
to a shock lung-like or acute respiratory 
distress syndrome-like syndrome (Duran 
et al., 2018). Suggested treatment is 
mainly supportive. Corticosteroids are 
proposed for their possible beneficial 
effect on the pulmonary capillary 
membrane, preventing pulmonary 
oedema (Mellor and Soni, 2001). The 
pathogenesis of oil embolisms after 
the use of oil-based contrast could be 
similar to that described after a bone 
marrow fat embolism, however, in the 
latter case it concerns autologous tissue, 
while in the case of the use of oil-based 
contrast it concerns foreign material. In 
the four cases with severe complications 
of oil embolisms that are summarized 
in this review, one case was treated 
with corticosteroids (Charawanamuttu 
et al., 1973), but in the other cases only 
supportive measures were reported.
In this systematic review of HSGs with 
oil-based contrast for subfertility, four 
cases of infection-related mortality 
were identified. It should be noted 
that these cases were all in the 1940s, 
when penicillin had been recently 
introduced and the treatment for 
infection was completely different from 
current practice (Bud, 2007). There 
are also reports in the literature of 
infection-related mortality following 
HSG with the use of water-based 
contrast (Lachmann, 1944). With the 
increased use and improvements of 
(prophylactic and therapeutic) antibiotics, 
the course of these infections has 
become less severe. The frequency of 
acute pelvic inflammatory disease after 
HSG is nowadays 0.5% with antibiotic 
prophylaxis and 1.4% without prophylaxis 
(Li et al., 2018).
There were more than twice the number 
of reports on oil remnants (n = 85) than 
lipogranuloma formation (n = 41) after 
HSG with the use of oil-based contrast. 
Lipogranuloma is a pathological diagnosis 
and may be missed if oil remnants are 
not sent for pathological examination. 
Lipogranuloma may result in adhesion 
formation (Grosskinsky et al., 1994).
After iodine exposure, there is an excess 
of iodine transportation into the thyroid 
gland. Through negative feedback, 
this causes a transient decrease in 
the synthesis of thyroid hormone, 
potentially leading to the development 
of subclinical hypothyroidism. The level 
of thyroid hormone production will 
normally be restored within 24–48 h. 
However, patients with underlying thyroid 
abnormalities may be unable to escape 
from this so-called acute Wolff–Chaikoff 
effect and therefore acquire an iodine-
induced (transient) overt hypothyroidism 
(Wolff and Chaikoff, 1948). This is 
in line with the results of the cohort 
study by Mekaru et al. (2008), which 
showed that 35.7% of women with a 
subclinical hypothyroidism develop overt 
hypothyroidism after an HSG with oil-
based contrast, compared with 0–2.2% 
of euthyroid women (Kaneshige et al., 
2015; Mekaru et al., 2008). Iodine-
induced (transient) hyperthyroidism can 
also occur in susceptible patients due 
to activation of quiescent nodules (Wolff 
and Chaikoff, 1948). This was shown in 
a case report of a woman with Graves’ 
disease, who developed hyperthyroidism 
after an HSG (Ishizuki et al., 1992).
Five out of eight studies included in this 
review, on maternal thyroid dysfunction 
after HSG, were performed in Japan. 
The effect of iodinated contrast on 
the thyroidal gland may vary between 
Japanese and Caucasian women, possibly 
because of a different background risk 
(i.e. iodine-rich diet). The consumption 
of iodine-rich foods by mothers in Japan 
has been shown to lead to neonatal 
hypothyroidism (Nishiyama et al., 2004). 
This may be reflected in the overall risk 
for congenital hypothyroidism, which is 
0.7% in Japan compared with 0.04% in 
the Netherlands (Tokyo Health Service 
Association, 2010; Verkerk et al., 2014). 
Data on Asian women suggest that 
neonatal thyroid dysfunction after HSG 
is related to the amount of oil-based 
contrast used during the procedure, 
although volume of contrast was not 
reported for all procedures (Satoh et al., 
2015).
It is unclear whether Caucasian women 
with an underlying thyroid disease are 
also at risk of developing hypothyroidism 
after an HSG with oil-based contrast. 
Until further studies have been 
performed, it is suggested that women 
with overt thyroid disease should not 
receive an HSG with oil-based contrast. 
In current practice, routine thyroid 
screening for women with subfertility 
varies. According to the NICE guidelines 
thyroid screening is not recommended 
as routine measurement in asymptomatic 
women presenting with subfertility 
(NICE, 2017). However, the ACOG 
committee opinion on fertility work-up 
does recommend routine thyroid testing 
for all subfertile women (ACOG, 2019). 
Moreover, the 2017 American Thyroid 
Association guidelines for the diagnosis 
and management of thyroid disease 
during pregnancy and the post-partum 
period advises maintaining serum TSH 
concentrations below 2.5 mIU/l pre-
conceptually in the subfertility setting 
(Alexander et al., 2017).
In this systematic review of complications 
of HSG from 1928 onwards, the most 
frequently reported complication with 
oil-based contrast is intravasation, 
occurring in 2.7%. Only four cases of 
serious consequences of oil embolisms 
in subfertile women have been published 
since 1928. Therefore, safety concerns 
should not be the reason to deny the use 
of oil-based contrast for tubal testing in 
women with unexplained subfertility.
Further studies on the effect of oil-based 
contrast on maternal and neonatal 
thyroid function in Caucasian women are 
suggested. Furthermore, future research 
should investigate the mechanism of 
the pregnancy-enhancing effect of oil-
based contrast. By gaining knowledge 
on the mechanism of action, it would 
be possible to determine which women 
would benefit most from an HSG with 
the use of oil-based contrast.
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